Published in Mod Pathol on May 23, 2008
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet (2009) 7.26
A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. Cancer Res (2008) 2.87
Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod Pathol (2009) 2.69
Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing. Genome Res (2010) 2.50
Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer (2010) 2.45
ETS gene fusions in prostate cancer. Nat Rev Urol (2009) 2.43
PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res (2011) 2.35
The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prev (2012) 2.13
Beyond PSA: the next generation of prostate cancer biomarkers. Sci Transl Med (2012) 2.00
The molecular pathology of cancer. Nat Rev Clin Oncol (2010) 1.86
Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas. Am J Surg Pathol (2011) 1.58
ETV1, 4 and 5: an oncogenic subfamily of ETS transcription factors. Biochim Biophys Acta (2012) 1.58
Oncogenic gene fusions in epithelial carcinomas. Curr Opin Genet Dev (2009) 1.51
ERG/AKR1C3/AR Constitutes a Feed-Forward Loop for AR Signaling in Prostate Cancer Cells. Clin Cancer Res (2015) 1.50
Prostate-specific G-protein-coupled receptor collaborates with loss of PTEN to promote prostate cancer progression. Oncogene (2015) 1.49
PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy. Clin Cancer Res (2011) 1.46
Novel diagnostic biomarkers for prostate cancer. J Cancer (2010) 1.36
Molecular circuits of solid tumors: prognostic and predictive tools for bedside use. Nat Rev Clin Oncol (2010) 1.36
Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer. Mod Pathol (2012) 1.35
TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features. Mod Pathol (2010) 1.23
PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate. Eur Urol (2014) 1.21
Clinical potential of the ERG oncoprotein in prostate cancer. Nat Rev Urol (2012) 1.17
Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer. Cancer Epidemiol Biomarkers Prev (2013) 1.17
Evidence for molecular differences in prostate cancer between African American and Caucasian men. Clin Cancer Res (2014) 1.15
Oncogenic activation of ERG: A predominant mechanism in prostate cancer. J Carcinog (2011) 1.13
Frequent gene products and molecular pathways altered in prostate cancer- and metastasis-initiating cells and their progenies and novel promising multitargeted therapies. Mol Med (2011) 1.13
Cytoplasmic PTEN protein loss distinguishes intraductal carcinoma of the prostate from high-grade prostatic intraepithelial neoplasia. Mod Pathol (2012) 1.07
Genomic Rearrangements of PTEN in Prostate Cancer. Front Oncol (2013) 1.07
TMPRSS2-ERG and PTEN loss in prostate cancer. Nat Genet (2009) 1.03
Prostate cancer genes associated with TMPRSS2-ERG gene fusion and prognostic of biochemical recurrence in multiple cohorts. Br J Cancer (2010) 1.03
Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer. Prostate Cancer Prostatic Dis (2015) 1.02
Mechanisms of persistent activation of the androgen receptor in CRPC: recent advances and future perspectives. World J Urol (2011) 0.99
Androgens Induce Functional CXCR4 through ERG Factor Expression in TMPRSS2-ERG Fusion-Positive Prostate Cancer Cells. Transl Oncol (2010) 0.99
A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer. J Natl Cancer Inst (2015) 0.99
Integrin-linked kinase as a target for ERG-mediated invasive properties in prostate cancer models. Carcinogenesis (2012) 0.98
Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma. Mod Pathol (2013) 0.97
TMPRSS2-ERG Fusion Gene Expression in Prostate Tumor Cells and Its Clinical and Biological Significance in Prostate Cancer Progression. J Cancer Sci Ther (2012) 0.97
Recurrent prostate cancer genomic alterations predict response to brachytherapy treatment. Cancer Epidemiol Biomarkers Prev (2014) 0.95
Mouse models of prostate cancer: picking the best model for the question. Cancer Metastasis Rev (2014) 0.93
Utility of PTEN and ERG immunostaining for distinguishing high-grade PIN from intraductal carcinoma of the prostate on needle biopsy. Am J Surg Pathol (2015) 0.93
ERG rearrangement is associated with prostate cancer-related death in Chinese prostate cancer patients. PLoS One (2014) 0.89
Disruption of prostate epithelial differentiation pathways and prostate cancer development. Front Oncol (2013) 0.89
Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN) and intraductal carcinoma through retrograde glandular colonization. J Pathol (2015) 0.87
ERG overexpression and PTEN status predict capsular penetration in prostate carcinoma. Prostate (2013) 0.86
Function of phosphorylation of NF-kB p65 ser536 in prostate cancer oncogenesis. Oncotarget (2015) 0.86
A three-marker FISH panel detects more genetic aberrations of AR, PTEN and TMPRSS2/ERG in castration-resistant or metastatic prostate cancers than in primary prostate tumors. PLoS One (2013) 0.86
PSA and beyond: alternative prostate cancer biomarkers. Cell Oncol (Dordr) (2016) 0.86
Cysteine- rich secretory protein 3 (CRISP3), ERG and PTEN define a molecular subtype of prostate cancer with implication to patients' prognosis. J Hematol Oncol (2014) 0.85
Emerging critical role of molecular testing in diagnostic genitourinary pathology. Arch Pathol Lab Med (2012) 0.85
Low Frequency of the ERG Oncogene Alterations in Prostate Cancer Patients from India. J Cancer (2013) 0.85
The role of treatment modality on the utility of predictive tissue biomarkers in clinical prostate cancer: a systematic review. J Cancer Res Clin Oncol (2012) 0.84
ERG immunohistochemistry and clinicopathologic characteristics in Korean prostate adenocarcinoma patients. Korean J Pathol (2012) 0.84
Discovery and Classification of Fusion Transcripts in Prostate Cancer and Normal Prostate Tissue. Am J Pathol (2015) 0.83
Differential cytotoxic activity of a novel palladium-based compound on prostate cell lines, primary prostate epithelial cells and prostate stem cells. PLoS One (2013) 0.82
Molecular characterization and clinical impact of TMPRSS2-ERG rearrangement on prostate cancer: comparison between FISH and RT-PCR. Biomed Res Int (2013) 0.82
Markers for detection of prostate cancer. Cancers (Basel) (2010) 0.82
ETS rearrangements in prostate cancer. Asian J Androl (2012) 0.82
Personalized management in low-risk prostate cancer: the role of biomarkers. Prostate Cancer (2012) 0.82
NKX3.1 Suppresses TMPRSS2-ERG Gene Rearrangement and Mediates Repair of Androgen Receptor-Induced DNA Damage. Cancer Res (2015) 0.81
Clinical variability and molecular heterogeneity in prostate cancer. Asian J Androl (2016) 0.81
DNA alterations in the tumor genome and their associations with clinical outcome in prostate cancer. Asian J Androl (2016) 0.81
Germ-line sequence variants of PTEN do not have an important role in hereditary and non-hereditary prostate cancer susceptibility. J Hum Genet (2011) 0.81
ERG induces epigenetic activation of Tudor domain-containing protein 1 (TDRD1) in ERG rearrangement-positive prostate cancer. PLoS One (2013) 0.81
Overexpression of ERG and Wild-Type PTEN Are Associated with Favorable Clinical Prognosis and Low Biochemical Recurrence in Prostate Cancer. PLoS One (2015) 0.80
Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH. Mod Pathol (2016) 0.80
PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas. Prostate (2015) 0.80
What is the Need for Prostatic Biomarkers in Prostate Cancer Management? Curr Urol Rep (2015) 0.80
PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer. Eur Urol Focus (2016) 0.79
Integrated analysis of the genomic instability of PTEN in clinically insignificant and significant prostate cancer. Mod Pathol (2015) 0.78
TMPRSS2-ERG fusion promotes prostate cancer metastases in bone. Oncotarget (2016) 0.78
Using molecular markers to help predict who will fail after radical prostatectomy. Prostate Cancer (2011) 0.78
Biologic differences between peripheral and transition zone prostate cancer. Prostate (2014) 0.78
Biomarkers for prostate cancer: present challenges and future opportunities. Future Sci OA (2015) 0.77
The role of TMPRSS2:ERG in molecular stratification of PCa and its association with tumor aggressiveness: a study in Brazilian patients. Sci Rep (2014) 0.77
ERG Protein Expression Is of Limited Prognostic Value in Men with Localized Prostate Cancer. ISRN Urol (2013) 0.77
A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195. Invest New Drugs (2015) 0.77
ERG expression in prostate cancer: biological relevance and clinical implication. J Cancer Res Clin Oncol (2015) 0.76
Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics. BMC Med (2016) 0.76
Multi-transcript profiling in archival diagnostic prostate cancer needle biopsies to evaluate biomarkers in non-surgically treated men. BMC Cancer (2014) 0.76
Translational and clinical implications of the genetic landscape of prostate cancer. Nat Rev Clin Oncol (2016) 0.76
Cancer Prognosis Defined by the Combined Analysis of 8q, PTEN and ERG. Transl Oncol (2016) 0.75
Androgen receptor CAG polymorphism and sporadic and early-onset prostate cancer among Mexican men. J Hum Genet (2016) 0.75
Molecular signatures in urologic tumors. Int J Mol Sci (2013) 0.75
Loss of PTEN expression in ERG-negative prostate cancer predicts secondary therapies and leads to shorter disease-specific survival time after radical prostatectomy. Mod Pathol (2016) 0.75
Colorimetric TMPRSS2-ERG Gene Fusion Detection in Prostate Cancer Urinary Samples via Recombinase Polymerase Amplification. Theranostics (2016) 0.75
Is There a Role for Genetic Information in Risk Assessment and Decision Making in Prostate Cancer? Nephrourol Mon (2016) 0.75
The ETS family of oncogenic transcription factors in solid tumours. Nat Rev Cancer (2017) 0.75
Emerging Role of Genomic Rearrangements in Breast Cancer: Applying Knowledge from Other Cancers. Biomark Cancer (2016) 0.75
Somatic molecular subtyping of prostate tumors from HOXB13 G84E carriers. Oncotarget (2017) 0.75
PTEN loss detection in prostate cancer: comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort. Oncotarget (2017) 0.75
Molecular alterations in prostate cancer and association with MRI features. Prostate Cancer Prostatic Dis (2017) 0.75
Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications. Ther Adv Med Oncol (2017) 0.75
Identification of human brain tumour initiating cells. Nature (2004) 38.87
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08
Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med (2014) 11.05
Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell (2009) 6.77
Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol (2008) 3.97
Mutations in SUFU predispose to medulloblastoma. Nat Genet (2002) 3.78
Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. Neoplasia (2006) 3.08
Optimizing nucleic acid extraction from thyroid fine-needle aspiration cells in stained slides, formalin-fixed/paraffin-embedded tissues, and long-term stored blood samples. Arq Bras Endocrinol Metabol (2012) 2.57
The role of Alu repeat clusters as mediators of recurrent chromosomal aberrations in tumors. Genes Chromosomes Cancer (2002) 2.57
Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. J Clin Oncol (2011) 2.36
Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias. Cancer Genet Cytogenet (2006) 2.23
Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood (2009) 2.22
PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J Pathol (2009) 2.13
Pediatric renal cell carcinoma: clinical, pathologic, and molecular abnormalities associated with the members of the mit transcription factor family. Am J Clin Pathol (2006) 2.09
A method for accurate detection of genomic microdeletions using real-time quantitative PCR. BMC Genomics (2005) 2.04
Loss of RB1 induces non-proliferative retinoma: increasing genomic instability correlates with progression to retinoblastoma. Hum Mol Genet (2008) 1.98
The RAG-1/2 endonuclease causes genomic instability and controls CNS complications of lymphoblastic leukemia in p53/Prkdc-deficient mice. Cancer Cell (2003) 1.90
Chromosomal localization of DNA amplifications in neuroblastoma tumors using cDNA microarray comparative genomic hybridization. Neoplasia (2003) 1.64
Double-barreled wet colostomy is a safe option for simultaneous urinary and fecal diversion. Analysis of 56 procedures from a single institution. J Surg Oncol (2006) 1.55
High-resolution mapping of amplifications and deletions in pediatric osteosarcoma by use of CGH analysis of cDNA microarrays. Genes Chromosomes Cancer (2003) 1.52
PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy. Clin Cancer Res (2011) 1.46
TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: implications for fusion status and DSB repair. Clin Cancer Res (2013) 1.45
Analysis of miRNA-gene expression-genomic profiles reveals complex mechanisms of microRNA deregulation in osteosarcoma. Cancer Genet (2011) 1.42
Association of the t(12;22)(q13;q12) EWS/ATF1 rearrangement with polyphenotypic round cell sarcoma of bone: a case report. Am J Surg Pathol (2005) 1.41
Abnormalities in villin gene expression and canalicular microvillus structure in progressive cholestatic liver disease of childhood. Lancet (2003) 1.41
Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. J Clin Oncol (2007) 1.40
Plk4 is required for cytokinesis and maintenance of chromosomal stability. Proc Natl Acad Sci U S A (2010) 1.40
Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma. Breast Cancer Res (2008) 1.38
The genetics of osteosarcoma. Sarcoma (2012) 1.33
Identification of interactive networks of gene expression associated with osteosarcoma oncogenesis by integrated molecular profiling. Hum Mol Genet (2009) 1.33
Identification of a novel gene NCRMS on chromosome 12q21 with differential expression between rhabdomyosarcoma subtypes. Oncogene (2002) 1.32
The CIC-DUX4 fusion transcript is present in a subgroup of pediatric primitive round cell sarcomas. Hum Pathol (2011) 1.29
Effects of THBS3, SPARC and SPP1 expression on biological behavior and survival in patients with osteosarcoma. BMC Cancer (2006) 1.29
ASAP1, a gene at 8q24, is associated with prostate cancer metastasis. Cancer Res (2008) 1.29
PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade. Mod Pathol (2012) 1.26
Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer. J Clin Oncol (2009) 1.25
Human telomere reverse transcriptase expression predicts progression and survival in pediatric intracranial ependymoma. J Clin Oncol (2006) 1.25
PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer. BJU Int (2011) 1.24
In vitro analysis of integrated global high-resolution DNA methylation profiling with genomic imbalance and gene expression in osteosarcoma. PLoS One (2008) 1.24
Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy. Cancer (2012) 1.23
Cytogenetically balanced translocations are associated with focal copy number alterations. Hum Genet (2006) 1.23
High-resolution mapping of genomic imbalance and identification of gene expression profiles associated with differential chemotherapy response in serous epithelial ovarian cancer. Neoplasia (2005) 1.22
Follicular lymphoma lacking the t(14;18)(q32;q21): identification of two disease subtypes. Br J Haematol (2003) 1.21
Primary subcutaneous primitive neuroectodermal tumor with aggressive behavior and an unusual karyotype: case report. Pediatr Dev Pathol (2004) 1.21
Defining a 0.5-mb region of genomic gain on chromosome 6p22 in bladder cancer by quantitative-multiplex polymerase chain reaction. Am J Pathol (2004) 1.21
Constitutional UPD for chromosome 11p15 in individuals with isolated hemihyperplasia is associated with high tumor risk and occurs following assisted reproductive technologies. Am J Med Genet A (2006) 1.21
Application of microarrays to the analysis of gene expression in cancer. Clin Chem (2002) 1.20
Establishment in severe combined immunodeficiency mice of subrenal capsule xenografts and transplantable tumor lines from a variety of primary human lung cancers: potential models for studying tumor progression-related changes. Clin Cancer Res (2006) 1.19
Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients. Breast Cancer Res Treat (2010) 1.19
An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line. Lab Invest (2005) 1.19
Direct profiling of cancer biomarkers in tumor tissue using a multiplexed nanostructured microelectrode integrated circuit. ACS Nano (2009) 1.19
Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistry. BMC Cancer (2009) 1.19
GLUT1 expression in malignant tumors and its use as an immunodiagnostic marker. Clinics (Sao Paulo) (2011) 1.19
Molecular characterization of deletion breakpoints in adults with 22q11 deletion syndrome. Hum Genet (2006) 1.17
The breakage-fusion-bridge (BFB) cycle as a mechanism for generating genetic heterogeneity in osteosarcoma. Chromosoma (2006) 1.17
One-hit effects in cancer: altered proteome of morphologically normal colon crypts in familial adenomatous polyposis. Cancer Res (2008) 1.14
Profiling genomic copy number changes in retinoblastoma beyond loss of RB1. Genes Chromosomes Cancer (2007) 1.14
Epigenetic silencing of CRABP2 and MX1 in head and neck tumors. Neoplasia (2009) 1.14
Expression analysis of genes associated with human osteosarcoma tumors shows correlation of RUNX2 overexpression with poor response to chemotherapy. BMC Cancer (2010) 1.13
The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Head Neck Oncol (2011) 1.13
Defective DNA strand break repair after DNA damage in prostate cancer cells: implications for genetic instability and prostate cancer progression. Cancer Res (2004) 1.13
Colorectal cancer "methylator phenotype": fact or artifact? Neoplasia (2005) 1.13
Genomic mechanisms and measurement of structural and numerical instability in cancer cells. Semin Cancer Biol (2006) 1.13
Detailed cytogenetic and array analysis of pediatric primitive sarcomas reveals a recurrent CIC-DUX4 fusion gene event. Cancer Genet Cytogenet (2009) 1.12
PTEN genomic deletions that characterize aggressive prostate cancer originate close to segmental duplications. Genes Chromosomes Cancer (2011) 1.11
An integrated mBAND and submegabase resolution tiling set (SMRT) CGH array analysis of focal amplification, microdeletions, and ladder structures consistent with breakage-fusion-bridge cycle events in osteosarcoma. Genes Chromosomes Cancer (2005) 1.10
Down-regulation of PHLDA1 gene expression is associated with breast cancer progression. Breast Cancer Res Treat (2007) 1.09
Clinical and molecular characteristics of pediatric gastrointestinal stromal tumors (GISTs). Pediatr Blood Cancer (2005) 1.08
Increased malignant behavior in neuroblastoma cells with acquired multi-drug resistance does not depend on P-gp expression. Int J Oncol (2005) 1.08
High-resolution array CGH identifies novel regions of genomic alteration in intermediate-risk prostate cancer. Prostate (2009) 1.08
Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration-resistant prostate cancer. Histopathology (2012) 1.06
The role of telomere maintenance in the spontaneous growth arrest of pediatric low-grade gliomas. Neoplasia (2006) 1.06
Loss of p53 enhances the induction of colitis-associated neoplasia by dextran sulfate sodium. Carcinogenesis (2007) 1.06
PTEN deletion and heme oxygenase-1 overexpression cooperate in prostate cancer progression and are associated with adverse clinical outcome. J Pathol (2011) 1.05
ERBB4 confers metastatic capacity in Ewing sarcoma. EMBO Mol Med (2013) 1.05
Parallel analysis of sporadic primary ovarian carcinomas by spectral karyotyping, comparative genomic hybridization, and expression microarrays. Cancer Res (2002) 1.04
Human salivary gland morphogenesis: myoepithelial cell maturation assessed by immunohistochemical markers. Histopathology (2010) 1.04
Spectral karyotyping identifies recurrent complex rearrangements of chromosomes 8, 17, and 20 in osteosarcomas. Genes Chromosomes Cancer (2003) 1.03